On Jan. 25, 2013, Pfizer announced the FDA had granted approval for the expansion of the companyﾒs pneumococcal conjugate vaccine, Prevnar 13ﾮ* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for use in older children and adolescents aged 6 years through 17 years for active immunization for the prevention of invasive disease caused by the 13 Streptococcus pneumoniae serotypes contained in the vaccine. For this age group, Prevnar 13 is administered as a one-time dose to patients who have never received Prevnar 13.